PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITOR AND PHARMACEUTICAL USE THEREFOR

摘要

The present invention addresses the problem of providing a low-molecular-weight compound having inhibitory activity against the function of proprotein convertase subtilisin/kexin type 9 (PCSK9). One aspect of the present invention relates to a compound represented by formula (I) (in the formula, n, R¹, R², R³, R⁴, R⁵, and R⁶ are as defined in the specification or in the claims), a pharmaceutically acceptable salt thereof, or a PCSK9 inhibitor containing a pharmaceutically acceptable solvate thereof as an active ingredient. Another aspect of the present invention relates to a drug that contains the PCSK9 inhibitor of the one aspect of the present invention as an active ingredient and that is for use in preventing or treating one or more symptoms, diseases, or disorders relating to PCSK9 function and selected from the group consisting of hypercholesterolemia, familial hypersterolemia, hyperlipidemia, arteriosclerosis, fatty liver, obesity, pancreatic beta cell failure, cholesteryl ester storage disease, Wolman disease, Niemann-Pick disease type C, symptoms in Hodgkin's lymphoma survivors, Tangier disease, Kawasaki disease, sitosterolemia, juvenile idiopathic arthritis, familial hypercholesterolemia, diabetes, symptoms in kidney transplant patients, and symptoms in heart transplant patients.